10 New Drugs for Primary Care: Q4 2019


Two first-in-class migraine drugs, the first generic version of NuvaRing®, and 7 more fourth quarter FDA-approved drugs for primary care.

While 2019 may be over, numerous medications were approved by the US Food and Drug Administration (FDA) during the fourth quarter of 2019 for conditions often seen in primary care.Below, you will find details on the first and only FDA-approved oral calcitonin gene-related peptide receptor antagonist for the treatment of migraine; the first topical minocycline to be approved for any condition; the first generic version of NuvaRing®; and 7 more. 

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Related Content
© 2023 MJH Life Sciences

All rights reserved.